ANTI-BLYS BIOLOGICS IN THE B-CELL TARGETED THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS: FOCUS ON EFFICACY AND SAFETY OF BELIMUMAB, ATACICEPT AND TABALUMAB.

dc.contributor.author	Dulficar, Fathima Fazla
dc.contributor.author	Dias, Sajani
dc.date.accessioned	2021-02-08T06:29:10Z
dc.date.available	2021-02-08T06:29:10Z
dc.date.issued	2019-06-15
dc.identifier.issn	2659-2193
dc.identifier.uri	http://220.247.247.85:8081/handle/123456789/37391
dc.description	Biology, BMS School of Science, Sri Lanka	en_US
dc.language.iso	en	en_US
dc.publisher	GARI Publisher	en_US
dc.relation.ispartofseries	Volume. 05;Issue. 01
dc.subject	Systemic lupus erythematous	en_US
dc.subject	B cells	en_US
dc.subject	autoantibodies	en_US
dc.subject	BLyS	en_US
dc.subject	anti-BLyS biologics	en_US
dc.title	ANTI-BLYS BIOLOGICS IN THE B-CELL TARGETED THERAPY OF SYSTEMIC LUPUS ERYTHEMATOSUS: FOCUS ON EFFICACY AND SAFETY OF BELIMUMAB, ATACICEPT AND TABALUMAB.	en_US
dc.type	Article	en_US
dc.identifier.accno	47179	en_US